Semaglutide vs Tirzepatide vs Retatrutide: How the Published Research Compares

These three compounds come up constantly together in metabolic peptide research, largely because they represent an escalating series of receptor targets.

The Mechanism Difference

• Semaglutide — a single-target GLP-1 receptor agonist.

• Tirzepatide — a dual GLP-1/GIP receptor agonist.

• Retatrutide — a triple GLP-1/GIP/glucagon receptor agonist.

  
  

What the Published Trials Have Reported

Published trial data has reported differing average weight-loss outcomes across these compounds' respective studies, with the multi-agonist compounds generally associated with larger reported effects than single-target agonists in their published trials. It's worth noting there are no direct head-to-head trials comparing all three at once — different trials, populations, and durations make comparisons informative but not a controlled race.

Regulatory Status Differs Too

Semaglutide and Tirzepatide are TGA-approved and available by prescription in Australia. Retatrutide remains an investigational compound and is not TGA-approved for human use — which is why it's supplied strictly for laboratory research purposes, not as a prescribed therapeutic.

This article is general research and educational information only. All products referenced are supplied strictly for laboratory and scientific research purposes, not for human consumption, and this content is not medical, dosing, or legal advice.